Orum to begin Phase I trial of ORM-1153 after FDA clearance

The study will focus on evaluating the tolerability, safety, pharmacokinetics and pharmacodynamics of ORM-1153.

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Company to host a conference call to discuss the ORM-1153 IND clearance and provide a high-level overview of the Phase 1 ...

Software Tree Launches ORM_Skyway to Automate the Bridge from Relational Databases to AI

Builds a governed, business-object path from enterprise DBs to AI agents, opening opportunities for AI platforms, data ...
Business Wire

Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the ...
Yahoo Finance

ORM Consultants Unveils Cutting-Edge Reputation Management Solutions for Businesses Worldwide

CHICAGO, IL / ACCESSWIRE / January 9, 2024 / To address the latest approach, ORM Consultations unleashes innovative reputation management solutions for businesses worldwide. The platform focuses on ...
IGN

Aquaman 2: Patrick Wilson Doesn't Think Orm Will Be Main Villain of Sequel

Patrick Wilson, who portrayed Orm (aka the Ocean Master) in Aquaman, says he doesn’t believe Orm will be the main villain of Aquaman 2. Reported by SyFy Wire, Wilson made this claim during an event ...